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Edited by Peter BrzezinskiAbstract Lipobeads are hydrogel beads surrounded by a lipid
bilayer membrane and have been developed to act as a cell
analogue. The FLAG-tagged M2 muscarinic receptor was
incorporated onto the surface of the Lipobead by incubating
pre-Lipobeads with proteoliposomes containing the receptor.
Receptors reconstituted onto the surface of the Lipobeads were
functional in that they bound the antagonists quinuclidinylbenz-
ilate and scopolamine with characteristic muscarinic aﬃnities.
This demonstrates the feasibility of using Lipobeads to study the
binding properties of the M2 muscarinic receptor and oﬀers a
promising approach to the study of transmembrane protein
biology in general.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Transmembrane receptor1. Introduction
Transmembrane proteins, such as receptors, have a hydro-
phobic transmembrane region that requires a complementary
amphiphilic environment to promote and maintain proper
folding and function of the protein. Transmembrane proteins
therefore are often studied in preparations of protein-enriched
membrane fragments and, upon solubilization, after sub-
sequent reconstitution in liposomes [1,2]. To overcome the
mechanical instability associated with these classical methods,
and to facilitate ease of handling, supported phospholipid
membranes on modiﬁed solid surfaces have been developed [3–
6]. The solid surfaces used to support phospholipid membranes
typically are made up of a ﬂat sheet of glass, silica, or a surface
coated with gold. We have reported previously on a method
for creating a supported phospholipid membrane on the sur-
face of a microscopic phospholipid hydrogel conjugate [7],
which we have called pre-Lipobeads. These are free hydrogel
beads formed with a certain density of phospholipids cova-
lently attached to the hydrogel surface. The hydrophobic an-
chors on the surface of the hydrogel pre-Lipobeads promote* Corresponding author. Fax: +1-416-978-8511.
E-mail address: p.pennefather@utoronto.ca (P.S. Pennefather).
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doi:10.1016/j.febslet.2004.03.124the self-assembly of a membrane on the bead surface when
exposed to liposomes, resulting in the formation of Lipobeads
[7] (Fig. 1A). More recently, we have conﬁrmed that the
Lipobead membrane is composed mostly of two leaﬂets of
phospholipid and has the ability to encapsulate large hydro-
philic solutes [8]. In the present study, we were interested
in determining whether transmembrane receptors could be
incorporated onto the surface of these Lipobeads and retain
native function.2. Materials and methods
2.1. Materials
Anti-FLAG m2-FITC conjugated antibody, carbachol, N -methyl-
scopolamine bromide, sodium deoxycholate, sodium cholate, egg
phosphatidylcholine (ePC), bovine serum phosphatidylserine (PS), and
cholesterol were obtained from Sigma–Aldrich, Canada. Scopolamine
hydrobromide and ())-quinuclidinylbenzilate (QNB) were from RBI-
Sigma. [3H]QNB (lot 3363717, 37 Ci/mmol; lot 3467373, 39 Ci/mmol)
was obtained from Perkin–Elmer Life Sciences. The ﬂuorescent
phospholipid 1-palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)ami-
no]caproyl]-sn-glycero-3-phosphocholine (PC-NBD) was purchased
from Avanti Polar Lipids (Alabaster, AL, USA). All other chemicals
used were of reagent grade.
2.2. Reconstitution of M2 muscarinic receptor in phospholipid vesicles
FLAG- and c-Myc-tagged M2 muscarinic receptors were expressed
in Sf9 cells and extracted in digitonin-cholate as described previously
[9]. Reconstitution was carried out essentially as described by Haga
et al. [10]. The following conditions are for reconstitution on a 2-mL
bed volume of Sephadex G-50 (ﬁne); they were scaled up accordingly
for larger volumes of reconstitution. Sephadex G-50 (ﬁne) was packed
in Disposaﬂex (0.8 cm diameter, Kontes), Poly-Prep (10 mL, Bio-Rad),
or Econo-Pac (20 mL, Bio-Rad) columns. Solubilized extracts were
concentrated 4–14-fold on Centricon-10 (Millipore) concentrators. The
concentrated extract (106–366 nM, 100 lL) was incubated with car-
bachol (10 mM) for 15 min on ice. Lipid vesicles consisted of 1.26 mg/
mL ePC:PS:cholesterol (10:10:1 by wt) in HEN buﬀer (160 mM NaCl,
20 mM N -[2-hydroxyethyl]piperazine-N 0-[2-ethane-sulfonic acid]
(HEPES), and 1 mM ethylenediaminetetraacetic acid (EDTA), pH
adjusted to 8.0 with KOH), supplemented with 0.18% sodium deoxy-
cholate and 0.04% sodium cholate, and were prepared by sonication.
The receptor and lipid suspension were mixed in a 1:1 ratio (200 lL)
and passed down to a column of Sephadex G-50 (ﬁne) (2 mL bed
volume) pre-equilibrated with HEN buﬀer. The column was washed
with HEN buﬀer (600 lL). The reconstituted receptor was collected in
the void volume by eluting with an additional 500 lL of HEN buﬀer.
The concentration of reconstituted receptor ranged from 9 to 53 nM,
as determined by [3H]QNB.
Fluorescently labeled lipid vesicles (ePC:PS:cholesterol:PC-NBD
11:12:1.2:1 by wt) were prepared in a manner similar to that describedation of European Biochemical Societies.
Scheme 1.
Fig. 1. Reconstitution of FLAG-tagged M2 muscarinic receptor onto
the surface of Lipobeads. (A) Schematic illustrating the formation of a
Lipobead. Empty phospholipid vesicles (C) or vesicles containing ei-
ther FLAG-tagged M2 receptor (B) or c-Myc-tagged M2 receptor (D)
were reconstituted onto the surface of Lipobeads. The beads were
stained with an anti-FLAG antibody conjugated to FITC and viewed
on a confocal microscope at a wavelength of 498 nm.
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equilibrated with HEN buﬀer. The UV absorbance of the last fraction
eluted from the column was measured at 464 nm. The phospholipid
concentration in this liposome preparation, estimated by UV absor-
bance spectroscopy, was 0.15 mg/mL or 0.23 mM, assuming an aver-
age molecular weight of 650 for the lipid.
2.3. Reconstitution of M2 muscarinic receptor on Lipobeads
Pre-Lipobeads were prepared using 5 mol% cross-linked poly(di-
methylacrylamide) beads with 33 wt% anchors in the surfactant
mixture (total mass of 90 mg) as described by Ng et al. [7]. The dry
beads (7 mg) were hydrated with HEN buﬀer (50 lL) for 10 min. The
wetted pre-Lipobeads were then incubated with 300 lL of receptor
proteoliposomes for 2 h at room temperature. Unbound vesicles were
removed by washing the Lipobeads four times with HEN buﬀer.
2.4. Antibody labeling of the proteolipobeads
The anti-FLAG antibody conjugated to FITC (28 lg/mL) was ad-
ded to the proteolipobead sample and incubated overnight at 4 C. The
Lipobead membranes remained impermeant to antibody which was
directed at an N terminal (extracellular) domain. The samples were
then washed four times with HEN buﬀer prior to confocal microscopy.
Laser scanning confocal microscopy images were obtained using a
Model 5.10 Carl Zeiss Axiovert 100M laser scanning confocal micro-
scope equipped with a 10/0.5 NA Fluar lens, an argon laser using the
488 nm line, a beam splitter HFT 488, and an emission ﬁlter BP505-
530. A pinhole of 120 lm in size was used with the 10 lens, which
corresponded to an optical section of 10 lm in thickness.
2.5. Binding assays and analysis of data
To obtain proteolipobeads for use in binding assays, proteolipo-
somes were incubated with carbachol (10 mM) for 15 min on ice prior
to their incorporation into the beads. The proteolipobeads were then
washed four times with ice-cold HEN buﬀer (1 mL) to remove free
proteoliposomes and carbachol. Solutions of [3H]QNB and any unla-
beled ligands (500 lL) were prepared in buﬀer A (250 mM KH2PO4, 8
mM EDTA, 100 mM MgCl2, 230 mM NaCl, 4 mM HEPES, and 1
mM phenylmethylsulfonyl ﬂuoride, pH adjusted to 7.60 with KOH)
and added to the washed proteolipobeads. The reaction mixture was
incubated at 30 C for 2 h. The reaction was terminated by decanting
the supernatant and washing the beads three times with ice-cold buﬀer
A (1 mL). Ready Protein+ (Beckman) scintillant was added to the
washed beads (5 mL), which were then assayed for radioactivity. Eachsample was counted twice for 10 min by liquid scintillation spec-
trometry. Assays were performed in duplicate.
Binding to proteoliposomes was measured essentially as described
previously [11]. Aliquots of the liposomal preparation (3 lL) were
added to buﬀer A (50 lL) containing [3H]QNB and any unlabeled li-
gands, and the mixture was incubated at 30 C for 2 h. Routine esti-
mates of capacity were performed at a saturating concentration of
[3H]QNB (100 nM). Non-speciﬁc binding was taken as total binding
in the presence of 1 mM unlabeled N -methylscopolamine. Bound ra-
dioligand was separated on a column of Sephadex G-50 (ﬁne)
(0.8 6.5 cm) pre-equilibrated and eluted with buﬀer B (20 mM HE-
PES, 20 mM NaCl, 1 mM EDTA, 5 mM MgSO4, and 0.017% digi-
tonin, adjusted to pH 7.40 with NaOH). All of the eluant, including the
void volume (1.65 mL), was collected and assayed for radioactivity.
All data were analyzed with total binding taken as the dependent
variable (Bobsd) and with the total concentrations of all ligands taken as
the independent variables. Analyses were based on Scheme 1, where
the radioligand (P) and an unlabeled ligand (A) compete for distinct
and mutually independent sites (Rj; j ¼ 1; 2; . . . ; n). Sites of type j
bind P and A with equilibrium dissociation constants KPj and KAj,
respectively, and constitute the fraction Fj of all sites (Fj ¼ ½Rjt=½Rt,
where ½Rt ¼
Pn
j¼1½Rjt). Total binding was calculated according to
Eq. (1), where Bsp represents the level of speciﬁc binding at the cor-
responding value of ½Pt and NS is the fraction of unbound radioligand
that appears as non-speciﬁc binding. Total speciﬁc binding was cal-
culated according to Eq. (2) and the required values of ½PRj were
obtained from the equation ½PRj ¼ ½P½Rj=KPj; the free concentra-
tions of receptor and each ligand ([P], [A]) were calculated numerically
from the corresponding total concentrations (½Rt, ½Pt, ½At) [12],
Bobsd ¼ Bsp þNSð½Pt  BspÞ; ð1Þ
Bsp ¼
Xn
j¼1
½PRj: ð2Þ
Further details regarding the analyses and related statistical proce-
dures have been described elsewhere [11–14].3. Results and discussion
It has been shown previously that c-Myc- and FLAG-tagged
forms of the human M2 muscarinic receptor can be expressed
in Sf9 cells and used as a rich source of receptor for bio-
chemical study [9]. The tagged receptor can be solubilized in
detergent and retains function in that it binds muscarinic an-
tagonists with characteristic aﬃnities [9,15]. In the current
investigation, we have extracted the muscarinic receptor from
Sf9 cells using digitonin-cholate and have reconstituted the
protein into liposomes. When the proteoliposomes are incu-
bated with hydrated pre-Lipobeads, the receptor is incorpo-
rated into the membrane that encapsulates the resulting
Lipobeads (Fig. 1A). FLAG-tagged receptor was detected at
the surface with an anti-FLAG antibody (Fig. 1B). Since the
FLAG epitope is at the amino terminus of the protein, at least
some receptors detected on the surface of the Lipobead are in a
proper orientation, with the amino terminal facing away from
the bead core. The anti-FLAG antibody was speciﬁc for its
epitope, as no staining was detected at the surface of Lipobe-
ads prepared with liposomes lacking receptor or with those
containing the c-Myc-tagged M2 muscarinic receptor (Fig. 1C
and D).
Table 2
Incorporation of receptor into liposomes and Lipobeads
Preparation FLAG-M2 muscarinic receptor Eﬃciency
a (%)
Proteoliposome
(pmol)
Proteolipobead
(fmol)
A 2.5 3.0 0.12
B 2.9 4.4 0.15
C 4.6 7.4 0.16
D 5.5 6.0 0.11
E 7.0 4.6 0.066
F 14.2 4.6 0.033
An aliquot of the proteoliposomal preparation (300 lL) was mixed
with pre-Lipobeads (7 mg, dry weight) as described in Section 2. The
amount of receptor taken from the liposomal preparation was inferred
from the best ﬁt of Scheme 1 to the data represented in Fig. 2A (i.e.,
½Rt) or estimated from the speciﬁc binding at a near-saturating con-
centration of [3H]QNB (100 nM). The amount of receptor incorpo-
rated into Lipobeads was inferred from the best ﬁt of Scheme 1 to the
data represented in Fig. 2B (i.e., ½R1t). The mean value for the six
preparations of proteolipobead is 5.0 0.6 fmol in a volume of 300 lL.
aEﬃciency of transfer of receptor from liposomes to Lipobeads.
346 P.-S.H. Park et al. / FEBS Letters 567 (2004) 344–348Receptors in liposomal vesicles and Lipobeads were char-
acterized in binding assays with the antagonists QNB and
scopolamine. The equilibrium dissociation constant of each
ligand was inferred from its inhibitory eﬀect on the speciﬁc
binding of [3H]QNB (Fig. 2). In both formulations, the mea-
sured muscarinic aﬃnities were similar to those observed
previously with extracts of muscarinic receptor from porcine
atria (Table 1) [11]. The eﬃciency of reconstitution of recep-
tors into liposomes was 35–98% with a mean of 61 8%
(N ¼ 7), as determined by [3H]QNB. The eﬃciency for incor-
poration of the reconstituted receptor into Lipobeads was
0.033–0.16% (Table 2).
The total concentration of reconstituted receptor in liposo-
mal preparations was 8–50 nM and the corresponding lipid
concentration was estimated to be 0.23 mM. Thus, there was
one receptor for every 4000–25 000 molecules of lipid. The
radius of a liposome was 15 nm as determined by dynamic
light scattering and the surface area was therefore 2.8 103
nm2. Since the surface area occupied by a single lipid molecule
in a phospholipid bilayer is roughly 0.60 nm2 [16], each lipo-
some contained about 4700 lipid molecules per leaﬂet of bi-
layer or 9400 lipid molecules overall. Each 300 lL aliquot of
the preparation therefore contained about 4.2 1016 moleculesTable 1
Aﬃnities of QNB and scopolamine for FLAG-tagged M2 muscarinic recept
Preparation QNB Sco
logKP1 logKP2 log
Proteoliposome )9.58 0.20 –a )7.
Proteolipobead )9.28 0.70 )6.10 0.71 )7.
The parametric values from the analyses represented in Fig. 2 are listed in t
aOne class of sites was suﬃcient for Scheme 1 to describe the data.
b The value of log KA2 was undeﬁned and was ﬁxed accordingly during the
c Fraction of sites exhibiting higher aﬃnity for QNB (i.e., KP1) and correspon
are 6.7 0.9 pM and 0.92 0.12 nM (N ¼ 3), respectively.
Fig. 2. Binding of QNB and scopolamine to FLAG-tagged M2 muscarinic r
bilized in digitonin-cholate and reconstituted in phospholipid vesicles (A)
concentration of [3H]QNB and graded concentrations of either unlabeled Q
unlabeled QNB shown in (B) (}) was measured in parallel with each full curv
each panel were analyzed simultaneously and the lines represent the best ﬁts o
with the same ligand (L  P or A) and it was assumed that KP ¼ KA for QNB.
of ½Rt was assigned to the data from each experiment. Each point represen
estimates of Bobsd were adjusted as described previously to obtain the corresp
the adjustment was taken as the mean of the individual values from the exp
1.2 0.1 nM, N ¼ 6). The mean values of log½Pt used for the adjustments in (
lower end of the x-axis indicate binding in the absence of unlabeled ligand.of lipid, 4.5 1012 liposomes, and from 1.5 1012 to 8.9 1012
molecules of receptor. It follows that there were 0.3–2 recep-
tors per liposome.or
polamine
KA1 logKA2 F1
22 0.19 –a –a
36 0.61 –b 0.007 0.01c
he table.
ﬁtting procedure (i.e., logKA2 > 1).
ding to the M2 muscarinic receptor. The mean values of ½R1 and ½R2t
eceptor. Membranes from Sf9 cells expressing the receptor were solu-
and Lipobeads (B). Total binding was measured at a sub-saturating
NB (s) or scopolamine (). A single point at the concentration of
e measured in the presence of scopolamine. The data for both ligands in
f Eq. (1). Single values of KLj were common to all of the data acquired
A single value of Fj was common to all of the data and a separate value
ts the mean of either three or four experiments (S.E.M.). Individual
onding values of Bsp plotted on the y-axis [10]. The value of ½Rt used in
eriments represented in each of the panels (A, 352 45 pM, N ¼ 7; B,
A) and (B) are )8.78 0.03 and )8.76 0.04, respectively. Points at the
The parametric values are listed in Table 1.
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obeads could be detected only when the proteoliposomes were
pre-incubated with the muscarinic agonist carbachol (10 mM)
prior to reconstitution with the beads. No speciﬁc binding was
observed when the Lipobeads were reconstituted with prote-
oliposomes that either were not pre-incubated with ligand or
were pre-incubated with the antagonist N-methylscopolamine
(1 lM) or [3H]QNB (3 nM). This suggests that the incorpo-
ration of functional receptor onto the surface of Lipobeads
requires a speciﬁc conformation that is favored by agonists but
not antagonists.
Binding of QNB to Lipobeads reconstituted with FLAG-
tagged receptor revealed two populations of sites. The sites of
higher aﬃnity resembled the receptor in phospholipid vesicles
(i.e., KP1 ¼ 0:3–0:5 nM, Table 1), whereas those of weaker
aﬃnity were found only with the beads (KP2 ¼ 0:8 lM). The
latter accounted for 28% of saturable binding at the concen-
tration of [3H]QNB used in the assays (Fig. 2B), or 99.3% of
the total capacity for the radioligand, and they presumably
derive from the bead itself. Binding of QNB to hydrated pre-
Lipobeads not exposed to liposomes revealed an aﬃnity that
was comparable to that of the low-aﬃnity site detected in the
proteolipobeads (i.e., 0.1 lM); also, the level of binding in-
creased with the level of cross-linking in the polymer (not
shown). This suggests that the cross-linked polymer forms
hydrophobic pockets that can bind QNB with a weak aﬃnity.
In contrast to QNB, the antagonist scopolamine bound to a
uniform population of sites on the reconstituted Lipobeads
(Fig. 2B). The aﬃnity of scopolamine for receptor on the beads
was the same as that for receptor in liposomes (Table 1) and
the corresponding capacity was equal to that of the high-af-
ﬁnity sites revealed by QNB (Fig. 2B). Scopolamine is more
hydrophilic than QNB and therefore would be expected to
have a weaker aﬃnity for non-receptor binding sites within the
core.
Receptors reconstituted onto the surface of the Lipobeads
therefore appear to be functional in that they bind muscarinic
antagonists with characteristic aﬃnities. The binding pocket of
the receptor is thought to be located approximately 9 A be-
neath the membrane surface [17] and its functional viability
very likely requires the proper arrangement of the seven
transmembrane a-helices. The retention of binding suggests
that neither the reconstitution procedure nor the presence of
the underlying hydrogel support caused signiﬁcant distortion
of protein folding, at least when the receptor was protected
with carbachol during reconstitution.
A minority of receptors was transferred from liposomes to
Lipobeads (Table 2) and the low eﬃciency can be attributed in
part to a ceiling imposed by the surface area of the latter. As
described above, a single liposome has a surface area of
2.8 103 lm2 (radius 0.015 lm). Since the Lipobeads used
here have a surface area of approximately 3.1 104 lm2 (ra-
dius 50 lm), about 1.1 107 liposomes will be required to
generate a bilayer over the entire surface of a Lipobead. If a
300 lL aliquot contains 4.5 1012 liposomes (see above),
complete uptake of the liposomes onto Lipobeads will require
about 4.1 105 beads. The actual number of Lipobeads can be
estimated from the total volume after hydration and the vol-
ume per bead. In hydrated Lipobeads, the measured volume
fraction of polymer was 20% (vol. polymer/vol. bead). We
therefore expect that 7 mg of dry beads will yield 0.035 cm3
(35 lL) of hydrated beads, given that Lipobeads have a densityof 1 g/cm3. Since the volume of a single bead is 5.2 107 cm3,
based on a radius of 0.005 cm, the mixture must contain about
6.7 104 beads, or 6-fold fewer than required to accommodate
all available liposomes. This suggests that a smaller amount of
proteoliposome could have been used to transfer the same
number of receptors to the Lipobeads, although a longer in-
cubation time might be required for the liposomes to ﬁnd and
to fuse with the beads.
The observed incorporation of receptor into Lipobeads was 5
pmol (Table 2, or 0.045 106 receptors per bead based on a
total of 67 000 beads. The predicted density is 3.6 106 recep-
tors per bead at the lowest concentration of receptor (i.e., 8 nM
or 1.5 1012 receptors in 300 lL), assuming that the level of
incorporation is limited by the number of beads. The predicted
density is 23 106 receptors per bead at the same concentration
of receptor, assuming that there are suﬃcient beads to accom-
modate all of the proteoliposomes. The bead-limited density is
therefore less than the theoretical maximum for that quantity of
proteoliposomes, but it remains 80-fold greater than the mea-
sured density. The source of this latter discrepancy is unclear. It
may derive from the inactivation of some receptors upon their
incorporation into the Lipobeads or from a failure of some
receptors to accompany the liposome lipid into the Lipobead
membrane. In any event, the data suggest that there is potential
for a substantial increase in the ratio of signal to noise.
The G protein-coupled receptors (GPCRs) are a major tar-
get for drug discovery [18]. A number of molecular assays, in
which puriﬁed GPCRs are reconstituted into a membrane
preparation, have been reported previously. Corning has a
receptor array in which GPCRs are incorporated into a sup-
ported lipid bilayer [19]. Biacore has produced a variant of
their surface plasmon resonance (SPR) technology where a
dextran coating on their SPR electrode is modiﬁed with surface
lipids that promote the fusion of solubilized GPCRs [20].
Nimbus Inc. reconstitutes transmembrane proteins into lipid
bilayers supported on porous silica cores [21], while Biovectors
Therapeutics S.A. uses polysaccharide cores [22]. Our method
represents an alternative approach to developing binding as-
says in which GPCRs are reconstituted into an easily manip-
ulated lipid bilayer environment.References
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